Monitoring Report: Respiratory Viruses - March 2024 Data

Samuel Gratzl, PhD Brianna M Goodwin Cartwright, MS Patricia J Rodriguez, PhD, MPH Charlotte Baker, DrPH, MPH, CPH Duy Do, PhD Nicholas L Stucky, MD, PhD

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:

Dr Nicholas Stucky Truveta, Inc 1745 114th Ave SE, Bellevue, WA 98004 Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through March 31, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and March 31, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 497,047 hospitalizations of 461,039 unique patients who tested positive for a respiratory virus between October 01, 2019 and March 31, 2024.


Overall, the rate of hospitalizations associated with respiratory viruses has decreased throughout March 2024 (-32.4%) compared to February 2024. While the main contributors, COVID-, influenza-, and RSV-associated hospitalizations each decreased (-56.7, -28.4, and -57.6%, respectively), all other respiratory viruses increased. The population over 65 years of age also saw a decrease in respiratory virus-associated hospitalizations (-37.0%), similar to the overall population. For infants and children, the rate of respiratory viruses associated-hospitalization slightly increased overall and for HMPV- parainfluenza-, and rhinovirus-associated hospitalizations. Rhinovirus-associated hospitalizations (1.7% of all hospitalizations in the last week of March 2024).

Discussion: We continue to see evidence that respiratory virus-associated hospitalizations peaked at end of 2023 and continue to decrease overall and for adults over 65. We see a slight increase in respiratory virus associated hospitalizations in the infant and children population, however rates are lower than seasonal highs. In February 2024, rhinovirus-associated hospitalizations were the main respiratory virus contributing to hospitalizations for infants and children, while COVID-associated hospitalizations were the largest contributor for the older adult population.

Trends in Surveillance

Overall population

Difference (percentage points)



Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout March 2024 (32.4% decrease since end of February 2024). Decreases in COVID- (-56.7%), influenza- (-28.4%), and RSV-associated hospitalizations (-57.6%) all contributed to this overall trend decrease. Associated hospitalizations for all other monitored respiratory viruses increased. In the last week of March 2024, respiratory virus-associated hospitalizations.

-0.3%

+0.1%

+0.0%


-0.2%

+0.0%

-0.9%


-1.2%

Infants and children (age 0-4)



	Overall	COVID	influenza	HMPV	parainfluenza virus	RSV	rhinovirus
February 26, 2024	3.0%	0.4%	n/a	0.6%	0.3%	0.6%	1.4%
March 25, 2024	3.2%	n/a	n/a	0.7%	0.4%	0.4%	1.7%
Change (percentage)	+4.1%			+18.9%	+24.3%	-37.8%	+17.8%
Difference (percentage points)	+0.1%			+0.1%	+0.1%	-0.2%	+0.3%

For the population between 0-4 years old, respiratory virus-associated hospitalizations slightly increased throughout March (+4.1%). RSV-associated hospitalizations decreased (-37.8%) while other respiratory viruses increased when counts were above reporting thresholds. In the last week of March, 3.2% of all hospitalizations in this age group were associated with a respiratory virus, and rhinovirus-associated hospitalizations were the largest individual contributor (1.7%).



Older adults (age 65 and over)

	Overall	COVID	influenza	HMPV	parainfluenza virus	RSV	rhinovirus
February 26, 2024	4.9%	2.6%	1.2%	0.3%	0.1%	0.4%	0.3%
March 25, 2024	3.1%	1.1%	0.9%	0.4%	0.2%	0.2%	0.3%
Change (percentage)	-37.0%	-57.2%	-24.8%	+32.2%	+51.7%	-55.3%	+5.0%
Difference (percentage points)	-1.8%	-1.5%	-0.3%	+0.1%	+0.1%	-0.2%	+0.0%

In the population over 65 years of age, there was a 37% decrease in hospitalizations associated with respiratory viruses. COVID-, influenza-, and RSV-associated hospitalizations all continued to decrease throughout the month, while HPMV-, parainfluenza-, and rhinovirus-associated hospitalizations each increased. In the last week of March, 3.1% of all hospitalizations in this age group were associated with a respiratory virus.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of highrisk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2019 and March 31, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on April 15, 2024 and included de-identified patient care data primarily located across ten states: Texas, New York, Florida, California, Washington, Illinois, North Carolina, Wisconsin, Oregon, and Pennsylvania.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first

day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population


Our study population consists of 497,047 hospitalizations of 461,039 unique patients (Table 1).

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
Ν	65,687 (100.00%)	131,415 (100.00%)	126,396 (100.00%)	88,277 (100.00%)	49,264 (100.00%)	461,039 (100.00%)
Age Group						
< 6 months	1,524 (2.32%)	1,403 (1.07%)	2,475 (1.96%)	2,811 (3.18%)	1,557 (3.16%)	9,770 (2.12%)
6 - <12 months	678 (1.03%)	472 (0.36%)	1,001 (0.79%)	1,350 (1.53%)	765 (1.55%)	4,266 (0.93%)
1 - <2 years	877 (1.34%)	789 (0.60%)	1,511 (1.20%)	1,850 (2.10%)	1,006 (2.04%)	6,033 (1.31%)
2 - 4 years	1,089 (1.66%)	902 (0.69%)	2,161 (1.71%)	2,793 (3.16%)	1,233 (2.50%)	8,178 (1.77%)
5 - 17 years	1,161 (1.77%)	1,828 (1.39%)	2,890 (2.29%)	3,221 (3.65%)	1,674 (3.40%)	10,774 (2.34%)
18 - 49 years	15,030 (22.88%)	33,244 (25.30%)	28,818 (22.80%)	13,181 (14.93%)	7,032 (14.27%)	97,305 (21.11%)
50 - 64 years	16,138 (24.57%)	32,857 (25.00%)	25,303 (20.02%)	13,709 (15.53%)	7,964 (16.17%)	95,971 (20.82%)
65 - 74 years	12,325 (18.76%)	26,135 (19.89%)	24,030 (19.01%)	16,637 (18.85%)	9,368 (19.02%)	88,495 (19.19%)
75 - 84 years	10,642 (16.20%)	21,877 (16.65%)	23,612 (18.68%)	19,325 (21.89%)	11,009 (22.35%)	86,465 (18.75%)
85+ years	6,223 (9.47%)	11,908 (9.06%)	14,595 (11.55%)	13,400 (15.18%)	7,656 (15.54%)	53,782 (11.67%)
Sex						
Female	32,808 (49.95%)	65,237 (49.64%)	66,218 (52.39%)	46,399 (52.56%)	26,267 (53.32%)	236,929 (51.39%)
Male	32,735 (49.83%)	65,898 (50.14%)	59,881 (47.38%)	41,732 (47.27%)	22,934 (46.55%)	223,180 (48.41%)
Other	n/a	n/a	n/a	n/a	n/a	n/a
Unknown	142 (0.22%)	277 (0.21%)	288 (0.23%)	144 (0.16%)	63 (0.13%)	930 (0.20%)
Race						
White	34,990 (53.27%)	83,631 (63.64%)	85,170 (67.38%)	57,820 (65.50%)	32,237 (65.44%)	293,848 (63.74%)
Black or African American	10,341 (15.74%)	16,007 (12.18%)	15,320 (12.12%)	10,643 (12.06%)	6,112 (12.41%)	58,423 (12.67%)
Asian	2,869 (4.37%)	4,003 (3.05%)	4,146 (3.28%)	3,875 (4.39%)	1,919 (3.90%)	16,812 (3.65%)

Native Hawaiian or Other Pacific Islander	385 (0.59%)	615 (0.47%)	719 (0.57%)	487 (0.55%)	295 (0.60%)	2,501 (0.54%)
American Indian or Alaska Native	292 (0.44%)	564 (0.43%)	690 (0.55%)	582 (0.66%)	248 (0.50%)	2,376 (0.52%)
Other Race	12,110 (18.44%)	18,793 (14.30%)	14,070 (11.13%)	9,675 (10.96%)	5,122 (10.40%)	59,770 (12.96%)
Declined to answer	313 (0.48%)	559 (0.43%)	552 (0.44%)	467 (0.53%)	341 (0.69%)	2,232 (0.48%)
Unknown	4,387 (6.68%)	7,243 (5.51%)	5,729 (4.53%)	4,728 (5.36%)	2,990 (6.07%)	25,077 (5.44%)
Ethnicity						
Hispanic or Latino	13,229 (20.14%)	21,674 (16.49%)	17,247 (13.65%)	12,292 (13.92%)	6,948 (14.10%)	71,390 (15.48%)
Not Hispanic or Latino	44,736 (68.10%)	96,510 (73.44%)	99,966 (79.09%)	70,075 (79.38%)	39,259 (79.69%)	350,546 (76.03%)
Declined to answer	306 (0.47%)	605 (0.46%)	592 (0.47%)	504 (0.57%)	316 (0.64%)	2,323 (0.50%)
Unknown	7,416 (11.29%)	12,626 (9.61%)	8,591 (6.80%)	5,406 (6.12%)	2,741 (5.56%)	36,780 (7.98%)
Virus						
COVID	42,471 (64.66%)	124,130 (94.46%)	110,568 (87.48%)	53,032 (60.07%)	23,259 (47.21%)	353,460 (76.67%)
HMPV	1,958 (2.98%)	129 (0.10%)	1,648 (1.30%)	3,425 (3.88%)	1,141 (2.32%)	8,301 (1.80%)
RSV	3,939 (6.00%)	1,469 (1.12%)	3,335 (2.64%)	6,027 (6.83%)	6,407 (13.01%)	21,177 (4.59%)
influenza	10,415 (15.86%)	145 (0.11%)	2,792 (2.21%)	10,974 (12.43%)	11,472 (23.29%)	35,798 (7.76%)
parainfluenza virus	959 (1.46%)	886 (0.67%)	1,577 (1.25%)	3,100 (3.51%)	1,036 (2.10%)	7,558 (1.64%)
rhinovirus	5,945 (9.05%)	4,656 (3.54%)	6,476 (5.12%)	11,719 (13.28%)	5,949 (12.08%)	34,745 (7.54%)
Comorbidity			'	'	'	'
Asthma	5,287 (8.05%)	8,566 (6.52%)	10,839 (8.58%)	9,901 (11.22%)	6,367 (12.92%)	40,960 (8.88%)
Chronic Lung Disease	3,293 (5.01%)	5,718 (4.35%)	6,360 (5.03%)	5,597 (6.34%)	3,628 (7.36%)	24,596 (5.33%)
Chronic Obstructive Pulmonary Disease	6,813 (10.37%)	11,883 (9.04%)	15,280 (12.09%)	13,105 (14.85%)	8,137 (16.52%)	55,218 (11.98%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.







Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019



Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019

COVID-19

Our COVID study population consists of 367,537 hospitalizations of 353,460 unique patients (Table 2).

Table 2: COVID patient characteristics by seasor
--

		-				
	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
Ν	42,471 (100.00%)	124,130 (100.00%)	110,568 (100.00%)	53,032 (100.00%)	23,259 (100.00%)	353,460 (100.00%)
Age Group						
< 6 months	109 (0.26%)	620 (0.50%)	1,057 (0.96%)	436 (0.82%)	190 (0.82%)	2,412 (0.68%)
6 - <12 months	13 (0.03%)	91 (0.07%)	253 (0.23%)	184 (0.35%)	86 (0.37%)	627 (0.18%)
1 - <2 years	16 (0.04%)	144 (0.12%)	334 (0.30%)	143 (0.27%)	78 (0.34%)	715 (0.20%)
2 - 4 years	25 (0.06%)	185 (0.15%)	427 (0.39%)	180 (0.34%)	67 (0.29%)	884 (0.25%)
5 - 17 years	237 (0.56%)	1,116 (0.90%)	1,468 (1.33%)	510 (0.96%)	183 (0.79%)	3,514 (0.99%)
18 - 49 years	11,383 (26.80%)	32,011 (25.79%)	26,619 (24.07%)	7,934 (14.96%)	2,692 (11.57%)	80,639 (22.81%)
50 - 64 years	11,631 (27.39%)	31,890 (25.69%)	23,250 (21.03%)	8,442 (15.92%)	3,363 (14.46%)	78,576 (22.23%)
65 - 74 years	8,323 (19.60%)	25,353 (20.42%)	22,001 (19.90%)	11,123 (20.97%)	4,907 (21.10%)	71,707 (20.29%)
75 - 84 years	6,928 (16.31%)	21,217 (17.09%)	21,759 (19.68%)	13,988 (26.38%)	6,727 (28.92%)	70,619 (19.98%)
85+ years	3,806 (8.96%)	11,503 (9.27%)	13,400 (12.12%)	10,092 (19.03%)	4,966 (21.35%)	43,767 (12.38%)
Sex		'	'	'		'
Female	20,414 (48.07%)	61,534 (49.57%)	58,031 (52.48%)	27,681 (52.20%)	12,086 (51.96%)	179,746 (50.85%)
Male	21,966 (51.72%)	62,328 (50.21%)	52,263 (47.27%)	25,248 (47.61%)	11,136 (47.88%)	172,941 (48.93%)
Other	n/a	n/a	n/a	n/a	n/a	n/a
Unknown	89 (0.21%)	265 (0.21%)	266 (0.24%)	101 (0.19%)	37 (0.16%)	758 (0.21%)
Race						
White	20,346 (47.91%)	79,580 (64.11%)	75,799 (68.55%)	36,534 (68.89%)	16,421 (70.60%)	228,680 (64.70%)
Black or African American	7,186 (16.92%)	14,769 (11.90%)	13,181 (11.92%)	5,904 (11.13%)	2,389 (10.27%)	43,429 (12.29%)
Asian	1,854 (4.37%)	3,684 (2.97%)	3,344 (3.02%)	2,096 (3.95%)	866 (3.72%)	11,844 (3.35%)

Native Hawaiian or Other Pacific Islander	227 (0.53%)	559 (0.45%)	546 (0.49%)	206 (0.39%)	89 (0.38%)	1,627 (0.46%)
American Indian or Alaska Native	169 (0.40%)	518 (0.42%)	544 (0.49%)	279 (0.53%)	114 (0.49%)	1,624 (0.46%)
Other Race	9,254 (21.79%)	17,564 (14.15%)	11,782 (10.66%)	5,045 (9.51%)	1,860 (8.00%)	45,505 (12.87%)
Declined to answer	224 (0.53%)	528 (0.43%)	463 (0.42%)	259 (0.49%)	140 (0.60%)	1,614 (0.46%)
Unknown	3,211 (7.56%)	6,928 (5.58%)	4,909 (4.44%)	2,709 (5.11%)	1,380 (5.93%)	19,137 (5.41%)
Ethnicity		'	'	'	'	'
Hispanic or Latino	10,012 (23.57%)	20,403 (16.44%)	14,513 (13.13%)	6,158 (11.61%)	2,456 (10.56%)	53,542 (15.15%)
Not Hispanic or Latino	26,855 (63.23%)	91,009 (73.32%)	87,844 (79.45%)	43,233 (81.52%)	19,302 (82.99%)	268,243 (75.89%)
Declined to answer	203 (0.48%)	570 (0.46%)	515 (0.47%)	295 (0.56%)	141 (0.61%)	1,724 (0.49%)
Unknown	5,401 (12.72%)	12,148 (9.79%)	7,696 (6.96%)	3,346 (6.31%)	1,360 (5.85%)	29,951 (8.47%)
Comorbidity						
Asthma	2,160 (5.09%)	7,542 (6.08%)	8,572 (7.75%)	4,755 (8.97%)	2,439 (10.49%)	25,468 (7.21%)
Chronic Lung Disease	1,425 (3.36%)	5,267 (4.24%)	5,325 (4.82%)	3,125 (5.89%)	1,723 (7.41%)	16,865 (4.77%)
Chronic Obstructive Pulmonary Disease	2,775 (6.53%)	10,982 (8.85%)	13,154 (11.90%)	7,719 (14.56%)	3,956 (17.01%)	38,586 (10.92%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 3. Figure 4 shows seasonal trends.

Figure 3: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2019




Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season



Influenza

Our influenza study population consists of 40,473 hospitalizations of 35,798 unique patients (Table 3).

Table 3: Influenza pa	tient characteristics	by season.
-----------------------	-----------------------	------------

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
Ν	10,415 (100.00%)	145 (100.00%)	2,792 (100.00%)	10,974 (100.00%)	11,472 (100.00%)	35,798 (100.00%)
Age Group						
< 6 months	146 (1.40%)	n/a	24 (0.86%)	67 (0.61%)	69 (0.60%)	306 (0.85%)
6 - <12 months	94 (0.90%)	n/a	13 (0.47%)	75 (0.68%)	43 (0.37%)	225 (0.63%)
1 - <2 years	148 (1.42%)	n/a	18 (0.64%)	103 (0.94%)	69 (0.60%)	339 (0.95%)
2 - 4 years	209 (2.01%)	n/a	54 (1.93%)	244 (2.22%)	176 (1.53%)	686 (1.92%)
5 - 17 years	336 (3.23%)	n/a	127 (4.55%)	541 (4.93%)	468 (4.08%)	1,477 (4.13%)
18 - 49 years	2,192 (21.05%)	27 (18.62%)	688 (24.64%)	2,348 (21.40%)	2,498 (21.77%)	7,753 (21.66%)
50 - 64 years	2,492 (23.93%)	42 (28.97%)	507 (18.16%)	2,160 (19.68%)	2,554 (22.26%)	7,755 (21.66%)
65 - 74 years	2,020 (19.40%)	20 (13.79%)	520 (18.62%)	2,188 (19.94%)	2,295 (20.01%)	7,043 (19.67%)
75 - 84 years	1,734 (16.65%)	31 (21.38%)	516 (18.48%)	2,087 (19.02%)	2,161 (18.84%)	6,529 (18.24%)
85+ years	1,044 (10.02%)	16 (11.03%)	325 (11.64%)	1,161 (10.58%)	1,139 (9.93%)	3,685 (10.29%)
Sex						'
Female	5,683 (54.57%)	81 (55.86%)	1,607 (57.56%)	6,112 (55.70%)	6,372 (55.54%)	19,855 (55.46%)
Male	4,707 (45.19%)	64 (44.14%)	1,182 (42.34%)	4,848 (44.18%)	5,093 (44.40%)	15,894 (44.40%)
Unknown	25 (0.24%)	n/a	n/a	14 (0.13%)	n/a	49 (0.14%)
Race						'
White	6,439 (61.82%)	87 (60.00%)	1,831 (65.58%)	6,969 (63.50%)	7,110 (61.98%)	22,436 (62.67%)
Black or African American	1,615 (15.51%)	35 (24.14%)	403 (14.43%)	1,586 (14.45%)	1,751 (15.26%)	5,390 (15.06%)
Asian	469 (4.50%)	n/a	92 (3.30%)	431 (3.93%)	433 (3.77%)	1,431 (4.00%)
Native Hawaiian or Other Pacific Islander	55 (0.53%)	n/a	35 (1.25%)	82 (0.75%)	85 (0.74%)	259 (0.72%)
American Indian or Alaska Native	48 (0.46%)	n/a	31 (1.11%)	100 (0.91%)	52 (0.45%)	231 (0.65%)
Other Race	1,226 (11.77%)	n/a	272 (9.74%)	1,193 (10.87%)	1,287 (11.22%)	3,987 (11.14%)
Declined to answer	41 (0.39%)	n/a	10 (0.36%)	44 (0.40%)	72 (0.63%)	167 (0.47%)
Unknown	522 (5.01%)	n/a	113 (4.05%)	569 (5.18%)	682 (5.94%)	1,897 (5.30%)
Ethnicity			· /			
Hispanic or Latino	1,418 (13.61%)	19 (13.10%)	394 (14.11%)	1,710 (15.58%)	1,859 (16.20%)	5,400 (15.08%)
Not Hispanic or Latino	8,037 (77.17%)	119 (82.07%)	2,236 (80.09%)	8,637 (78.70%)	8,952 (78.03%)	27,981 (78.16%)
Declined to answer	49 (0.47%)	n/a	n/a	54 (0.49%)	73 (0.64%)	185 (0.52%)
Unknown	911 (8.75%)	n/a	153 (5.48%)	573 (5.22%)	588 (5.13%)	2,232 (6.23%)

Comorbidity						
Asthma	1,257 (12.07%)	15 (10.34%)	406 (14.54%)	1,582 (14.42%)	1,694 (14.77%)	4,954 (13.84%)
Chronic Lung Disease	684 (6.57%)	n/a	205 (7.34%)	836 (7.62%)	874 (7.62%)	2,605 (7.28%)
Chronic Obstructive Pulmonary Disease	1,633 (15.68%)	16 (11.03%)	490 (17.55%)	1,950 (17.77%)	1,975 (17.22%)	6,064 (16.94%)


Hospitalization rate over time


The rate of influenza-associated hospitalization is shown in Figure 5. Figure 6 shows seasonal trends.

Figure 5: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2019









Human metapneumovirus (HMPV)


Our HMPV study population consists of 9,909 hospitalizations of 8,301 unique patients (Table 4).

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overal
Ν	1,958 (100.00%)	129 (100.00%)	1,648 (100.00%)	3,425 (100.00%)	1,141 (100.00%)	8,301 (100.00%)
Age Group						
< 6 months	50 (2.55%)	10 (7.75%)	52 (3.16%)	156 (4.55%)	41 (3.59%)	309 (3.72%)
6 - <12 months	68 (3.47%)	n/a	85 (5.16%)	115 (3.36%)	47 (4.12%)	320 (3.85%)
1 - <2 years	69 (3.52%)	21 (16.28%)	126 (7.65%)	161 (4.70%)	62 (5.43%)	439 (5.29%)
2 - 4 years	81 (4.14%)	22 (17.05%)	203 (12.32%)	270 (7.88%)	69 (6.05%)	645 (7.77%)
5 - 17 years	53 (2.71%)	n/a	103 (6.25%)	179 (5.23%)	56 (4.91%)	399 (4.81%)
18 - 49 years	209 (10.67%)	16 (12.40%)	185 (11.23%)	327 (9.55%)	140 (12.27%)	877 (10.56%)
50 - 64 years	362 (18.49%)	12 (9.30%)	249 (15.11%)	529 (15.45%)	185 (16.21%)	1,337 (16.11%)
65 - 74 years	389 (19.87%)	15 (11.63%)	249 (15.11%)	624 (18.22%)	193 (16.91%)	1,470 (17.71%)
75 - 84 years	402 (20.53%)	13 (10.08%)	240 (14.56%)	638 (18.63%)	192 (16.83%)	1,485 (17.89%)
85+ years	275 (14.04%)	n/a	156 (9.47%)	426 (12.44%)	156 (13.67%)	1,020 (12.29%)
Sex						
Female	1,127 (57.56%)	64 (49.61%)	964 (58.50%)	1,986 (57.99%)	687 (60.21%)	4,828 (58.16%)
Male	830 (42.39%)	65 (50.39%)	681 (41.32%)	1,434 (41.87%)	454 (39.79%)	3,464 (41.73%)
Unknown	n/a	n/a	n/a	n/a	n/a	n/a
Race						
White	1,398 (71.40%)	58 (44.96%)	1,074 (65.17%)	2,217 (64.73%)	684 (59.95%)	5,431 (65.43%)
Black or African American	184 (9.40%)	18 (13.95%)	157 (9.53%)	327 (9.55%)	138 (12.09%)	824 (9.93%)
Asian	64 (3.27%)	n/a	71 (4.31%)	163 (4.76%)	44 (3.86%)	346 (4.17%)
Native Hawaiian or Other Pacific Islander	13 (0.66%)	n/a	14 (0.85%)	10 (0.29%)	n/a	40 (0.48%)
American Indian or Alaska Native	10 (0.51%)	n/a	n/a	25 (0.73%)	n/a	46 (0.55%)
Other Race	206 (10.52%)	43 (33.33%)	238 (14.44%)	457 (13.34%)	187 (16.39%)	1,131 (13.62%)
Declined to answer	n/a	n/a	12 (0.73%)	24 (0.70%)	10 (0.88%)	53 (0.64%)
Unknown	76 (3.88%)	n/a	69 (4.19%)	202 (5.90%)	73 (6.40%)	430 (5.18%)
Ethnicity						
Hispanic or Latino	241 (12.31%)	40 (31.01%)	282 (17.11%)	583 (17.02%)	240 (21.03%)	1,386 (16.70%)
Not Hispanic or Latino	1,567 (80.03%)	82 (63.57%)	1,264 (76.70%)	2,633 (76.88%)	840 (73.62%)	6,386 (76.93%
Declined to answer	10 (0.51%)	n/a	n/a	19 (0.55%)	11 (0.96%)	45 (0.54%)
Unknown	140 (7.15%)	n/a	98 (5.95%)	190 (5.55%)	50 (4.38%)	484 (5.83%
Comorbidity			·		·	
Asthma	276 (14.10%)	16 (12.40%)	256 (15.53%)	487 (14.22%)	206 (18.05%)	1,241 (14.95%)
Chronic Lung Disease	208 (10.62%)	n/a	142 (8.62%)	277 (8.09%)	90 (7.89%)	721 (8.69%
Chronic Obstructive Pulmonary Disease	388 (19.82%)	n/a	264 (16.02%)	555 (16.20%)	160 (14.02%)	1,375 (16.56%)

Table 4: HMPV patient characteristics by season.

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 7. Figure 8 shows seasonal trends.







Figure 8: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season



Parainfluenza virus

Our parainfluenza virus study population consists of 9,295 hospitalizations of 7,558 unique patients (Table 5).


	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
Ν	959 (100.00%)	886 (100.00%)	1,577 (100.00%)	3,100 (100.00%)	1,036 (100.00%)	7,558 (100.00%)
Age Group						
< 6 months	51 (5.32%)	53 (5.98%)	100 (6.34%)	168 (5.42%)	62 (5.98%)	434 (5.74%)
6 - <12 months	28 (2.92%)	43 (4.85%)	68 (4.31%)	125 (4.03%)	28 (2.70%)	292 (3.86%)
1 - <2 years	47 (4.90%)	71 (8.01%)	99 (6.28%)	150 (4.84%)	63 (6.08%)	430 (5.69%)
2 - 4 years	60 (6.26%)	85 (9.59%)	154 (9.77%)	232 (7.48%)	74 (7.14%)	605 (8.00%)
5 - 17 years	44 (4.59%)	68 (7.67%)	109 (6.91%)	183 (5.90%)	70 (6.76%)	474 (6.27%)
18 - 49 years	93 (9.70%)	129 (14.56%)	193 (12.24%)	353 (11.39%)	139 (13.42%)	907 (12.00%)
50 - 64 years	169 (17.62%)	138 (15.58%)	240 (15.22%)	479 (15.45%)	145 (14.00%)	1,171 (15.49%)
65 - 74 years	163 (17.00%)	124 (14.00%)	254 (16.11%)	490 (15.81%)	175 (16.89%)	1,206 (15.96%)
75 - 84 years	176 (18.35%)	106 (11.96%)	209 (13.25%)	554 (17.87%)	174 (16.80%)	1,219 (16.13%)
85+ years	128 (13.35%)	69 (7.79%)	151 (9.58%)	366 (11.81%)	106 (10.23%)	820 (10.85%)

Table 5: Parainfluenza virus patient characteristics by season.

Sex						
Female	520 (54.22%)	459 (51.81%)	859 (54.47%)	1,657 (53.45%)	568 (54.83%)	4,063 (53.76%)
Male	435 (45.36%)	425 (47.97%)	712 (45.15%)	1,437 (46.35%)	466 (44.98%)	3,475 (45.98%)
Unknown	n/a	n/a	n/a	n/a	n/a	19 (0.25%)
Race						
White	638 (66.53%)	526 (59.37%)	959 (60.81%)	1,918 (61.87%)	594 (57.34%)	4,635 (61.33%)
Black or African American	105 (10.95%)	125 (14.11%)	176 (11.16%)	353 (11.39%)	153 (14.77%)	912 (12.07%)
Asian	57 (5.94%)	41 (4.63%)	92 (5.83%)	178 (5.74%)	40 (3.86%)	408 (5.40%)
Native Hawaiian or Other Pacific Islander	12 (1.25%)	n/a	n/a	14 (0.45%)	n/a	47 (0.62%)
American Indian or Alaska Native	n/a	n/a	15 (0.95%)	23 (0.74%)	n/a	53 (0.70%)
Other Race	97 (10.11%)	136 (15.35%)	224 (14.20%)	428 (13.81%)	154 (14.86%)	1,039 (13.75%)
Declined to answer	n/a	n/a	11 (0.70%)	23 (0.74%)	11 (1.06%)	53 (0.70%)
Unknown	37 (3.86%)	43 (4.85%)	87 (5.52%)	156 (5.03%)	70 (6.76%)	411 (5.44%)
Ethnicity						
Hispanic or Latino	93 (9.70%)	146 (16.48%)	255 (16.17%)	507 (16.35%)	203 (19.59%)	1,204 (15.93%)
Not Hispanic or Latino	768 (80.08%)	661 (74.60%)	1,214 (76.98%)	2,381 (76.81%)	773 (74.61%)	5,797 (76.70%)
Declined to answer	n/a	n/a	12 (0.76%)	20 (0.65%)	n/a	44 (0.58%)
Unknown	94 (9.80%)	76 (8.58%)	96 (6.09%)	192 (6.19%)	55 (5.31%)	513 (6.79%)
Comorbidity						
Asthma	140 (14.60%)	108 (12.19%)	224 (14.20%)	442 (14.26%)	152 (14.67%)	1,066 (14.10%)
Chronic Lung Disease	108 (11.26%)	54 (6.09%)	150 (9.51%)	256 (8.26%)	77 (7.43%)	645 (8.53%)
Chronic Obstructive Pulmonary Disease	197 (20.54%)	136 (15.35%)	276 (17.50%)	548 (17.68%)	171 (16.51%)	1,328 (17.57%)

Hospitalization rate over time

The rate of parainfluenza virus-associated hospitalization is shown in Figure 9. Figure 10 shows seasonal trends.








Figure 10: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions by season

Respiratory syncytial virus (RSV)

Our RSV study population consists of 26,898 hospitalizations of 21,177 unique patients (Table 6).

Table 6: RSV patient charact	teristics by season.
------------------------------	----------------------

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
Ν	3,939 (100.00%)	1,469 (100.00%)	3,335 (100.00%)	6,027 (100.00%)	6,407 (100.00%)	21,177 (100.00%)
Age Group						
< 6 months	788 (20.01%)	424 (28.86%)	716 (21.47%)	1,230 (20.41%)	857 (13.38%)	4,015 (18.96%)
6 - <12 months	286 (7.26%)	125 (8.51%)	261 (7.83%)	451 (7.48%)	347 (5.42%)	1,470 (6.94%)
1 - <2 years	293 (7.44%)	170 (11.57%)	313 (9.39%)	546 (9.06%)	389 (6.07%)	1,711 (8.08%)
2 - 4 years	296 (7.51%)	126 (8.58%)	327 (9.81%)	635 (10.54%)	352 (5.49%)	1,736 (8.20%)
5 - 17 years	68 (1.73%)	34 (2.31%)	120 (3.60%)	228 (3.78%)	174 (2.72%)	624 (2.95%)
18 - 49 years	212 (5.38%)	119 (8.10%)	287 (8.61%)	449 (7.45%)	545 (8.51%)	1,612 (7.61%)
50 - 64 years	445 (11.30%)	152 (10.35%)	359 (10.76%)	564 (9.36%)	868 (13.55%)	2,388 (11.28%)
65 - 74 years	544 (13.81%)	131 (8.92%)	361 (10.82%)	713 (11.83%)	986 (15.39%)	2,735 (12.91%)
75 - 84 years	598 (15.18%)	121 (8.24%)	366 (10.97%)	743 (12.33%)	1,062 (16.58%)	2,890 (13.65%)
85+ years	409 (10.38%)	67 (4.56%)	225 (6.75%)	468 (7.77%)	827 (12.91%)	1,996 (9.43%)
Sex						
Female	2,117 (53.74%)	791 (53.85%)	1,706 (51.15%)	3,167 (52.55%)	3,551 (55.42%)	11,332 (53.51%)
Male	1,813 (46.03%)	678 (46.15%)	1,627 (48.79%)	2,857 (47.40%)	2,846 (44.42%)	9,821 (46.38%)
Unknown	n/a	n/a	n/a	n/a	10 (0.16%)	24 (0.11%)
Race						
White	2,416 (61.34%)	770 (52.42%)	2,002 (60.03%)	3,595 (59.65%)	4,094 (63.90%)	12,877 (60.81%)
Black or African American	458 (11.63%)	310 (21.10%)	424 (12.71%)	729 (12.10%)	756 (11.80%)	2,677 (12.64%)
Asian	163 (4.14%)	49 (3.34%)	182 (5.46%)	408 (6.77%)	300 (4.68%)	1,102 (5.20%)
Native Hawaiian or Other Pacific Islander	35 (0.89%)	12 (0.82%)	67 (2.01%)	130 (2.16%)	90 (1.40%)	334 (1.58%)
American Indian or Alaska Native	20 (0.51%)	n/a	41 (1.23%)	48 (0.80%)	43 (0.67%)	158 (0.75%)

Other Race	608 (15.44%)	247 (16.81%)	434 (13.01%)	742 (12.31%)	671 (10.47%)	2,702 (12.76%)			
Declined to answer	n/a	n/a	17 (0.51%)	34 (0.56%)	46 (0.72%)	114 (0.54%)			
Unknown	230 (5.84%)	64 (4.36%)	161 (4.83%)	341 (5.66%)	407 (6.35%)	1,213 (5.73%)			
Ethnicity									
Hispanic or Latino	696 (17.67%)	310 (21.10%)	610 (18.29%)	1,119 (18.57%)	1,056 (16.48%)	3,791 (17.90%)			
Not Hispanic or Latino	2,866 (72.76%)	1,051 (71.55%)	2,539 (76.13%)	4,500 (74.66%)	4,956 (77.35%)	15,912 (75.14%)			
Declined to answer	12 (0.30%)	n/a	17 (0.51%)	46 (0.76%)	38 (0.59%)	121 (0.57%)			
Unknown	365 (9.27%)	100 (6.81%)	169 (5.07%)	362 (6.01%)	357 (5.57%)	1,353 (6.39%)			
Comorbidity									
Asthma	451 (11.45%)	126 (8.58%)	358 (10.73%)	710 (11.78%)	873 (13.63%)	2,518 (11.89%)			
Chronic Lung Disease	263 (6.68%)	62 (4.22%)	167 (5.01%)	343 (5.69%)	457 (7.13%)	1,292 (6.10%)			
Chronic Obstructive Pulmonary Disease	667 (16.93%)	137 (9.33%)	434 (13.01%)	833 (13.82%)	1,100 (17.17%)	3,171 (14.97%)			

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 11. Figure 12 shows seasonal trends.







Figure 12: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



Rhinovirus

Our rhinovirus study population consists of 42,935 hospitalizations of 34,745 unique patients (Table 7).

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
Ν	5,945 (100.00%)	4,656 (100.00%)	6,476 (100.00%)	11,719 (100.00%)	5,949 (100.00%)	34,745 (100.00%)
Age Group					'	
< 6 months	380 (6.39%)	296 (6.36%)	526 (8.12%)	754 (6.43%)	338 (5.68%)	2,294 (6.60%)
6 - <12 months	189 (3.18%)	208 (4.47%)	321 (4.96%)	400 (3.41%)	214 (3.60%)	1,332 (3.83%)
1 - <2 years	304 (5.11%)	382 (8.20%)	621 (9.59%)	747 (6.37%)	345 (5.80%)	2,399 (6.90%)
2 - 4 years	418 (7.03%)	481 (10.33%)	996 (15.38%)	1,232 (10.51%)	495 (8.32%)	3,622 (10.42%)
5 - 17 years	423 (7.12%)	597 (12.82%)	963 (14.87%)	1,580 (13.48%)	723 (12.15%)	4,286 (12.34%)
18 - 49 years	941 (15.83%)	942 (20.23%)	846 (13.06%)	1,770 (15.10%)	1,018 (17.11%)	5,517 (15.88%)
50 - 64 years	1,039 (17.48%)	623 (13.38%)	698 (10.78%)	1,535 (13.10%)	849 (14.27%)	4,744 (13.65%)
65 - 74 years	886 (14.90%)	492 (10.57%)	645 (9.96%)	1,499 (12.79%)	812 (13.65%)	4,334 (12.47%)
75 - 84 years	804 (13.52%)	389 (8.35%)	522 (8.06%)	1,315 (11.22%)	693 (11.65%)	3,723 (10.72%)
85+ years	561 (9.44%)	246 (5.28%)	338 (5.22%)	887 (7.57%)	462 (7.77%)	2,494 (7.18%)
Sex						
Female	2,947 (49.57%)	2,308 (49.57%)	3,051 (47.11%)	5,796 (49.46%)	3,003 (50.48%)	17,105 (49.23%)
Male	2,984 (50.19%)	2,338 (50.21%)	3,416 (52.75%)	5,908 (50.41%)	2,939 (49.40%)	17,585 (50.61%)
Unknown	14 (0.24%)	10 (0.21%)	n/a	15 (0.13%)	n/a	55 (0.16%)
Race						
White	3,753 (63.13%)	2,610 (56.06%)	3,505 (54.12%)	6,587 (56.21%)	3,334 (56.04%)	19,789 (56.95%)
Black or African American	793 (13.34%)	750 (16.11%)	979 (15.12%)	1,744 (14.88%)	925 (15.55%)	5,191 (14.94%)
Asian	262 (4.41%)	219 (4.70%)	365 (5.64%)	599 (5.11%)	236 (3.97%)	1,681 (4.84%)
Native Hawaiian or Other Pacific Islander	43 (0.72%)	38 (0.82%)	49 (0.76%)	45 (0.38%)	19 (0.32%)	194 (0.56%)
American Indian or Alaska Native	41 (0.69%)	34 (0.73%)	50 (0.77%)	107 (0.91%)	32 (0.54%)	264 (0.76%)
Other Race	719 (12.09%)	794 (17.05%)	1,120 (17.29%)	1,810 (15.45%)	963 (16.19%)	5,406 (15.56%)
Declined to answer	28 (0.47%)	19 (0.41%)	39 (0.60%)	83 (0.71%)	62 (1.04%)	231 (0.66%)
Unknown	306 (5.15%)	186 (3.99%)	369 (5.70%)	744 (6.35%)	378 (6.35%)	1,989 (5.72%)
Ethnicity						
Hispanic or Latino	769 (12.94%)	756 (16.24%)	1,193 (18.42%)	2,215 (18.90%)	1,134 (19.06%)	6,067 (17.46%)
Not Hispanic or Latino	4,643 (78.10%)	3,588 (77.06%)	4,869 (75.19%)	8,691 (74.16%)	4,436 (74.57%)	26,227 (75.48%)
Declined to answer	28 (0.47%)	23 (0.49%)	35 (0.54%)	70 (0.60%)	48 (0.81%)	204 (0.59%)
Unknown	505 (8.49%)	289 (6.21%)	379 (5.85%)	743 (6.34%)	331 (5.56%)	2,247 (6.47%)
Comorbidity	1	1	I		1	1
Asthma	1,003 (16.87%)	759 (16.30%)	1,023 (15.80%)	1,925 (16.43%)	1,003 (16.86%)	5,713 (16.44%)
Chronic Lung Disease	605 (10.18%)	325 (6.98%)	371 (5.73%)	760 (6.49%)	407 (6.84%)	2,468 (7.10%)
Chronic Obstructive Pulmonary Disease	1,153 (19.39%)	604 (12.97%)	662 (10.22%)	1,500 (12.80%)	775 (13.03%)	4,694 (13.51%)

Tab	le	7: I	Rhir	iovirus	patient	ch	aracter	ristics	by season.
-----	----	------	------	---------	---------	----	---------	---------	------------

Hospitalization rate over time


The rate of rhinovirus-associated hospitalization is shown in Figure 13. Figure 14 shows seasonal trends.

Figure 13: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 14: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season





Infants and children (age 0-4)

Our infants and children study population consists of 35,463 hospitalizations of 28,247 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
Ν	4,168 (100.00%)	3,566 (100.00%)	7,148 (100.00%)	8,804 (100.00%)	4,561 (100.00%)	28,247 (100.00%)
Age Group						
< 6 months	1,524 (36.56%)	1,403 (39.34%)	2,475 (34.63%)	2,811 (31.93%)	1,557 (34.14%)	9,770 (34.59%)
6 - <12 months	678 (16.27%)	472 (13.24%)	1,001 (14.00%)	1,350 (15.33%)	765 (16.77%)	4,266 (15.10%)
1 - <2 years	877 (21.04%)	789 (22.13%)	1,511 (21.14%)	1,850 (21.01%)	1,006 (22.06%)	6,033 (21.36%)
2 - 4 years	1,089 (26.13%)	902 (25.29%)	2,161 (30.23%)	2,793 (31.72%)	1,233 (27.03%)	8,178 (28.95%)

Sex						
Female	1,825 (43.79%)	1,541 (43.21%)	3,027 (42.35%)	3,764 (42.75%)	1,994 (43.72%)	12,151 (43.02%)
Male	2,330 (55.90%)	2,020 (56.65%)	4,114 (57.55%)	5,035 (57.19%)	2,561 (56.15%)	16,060 (56.86%)
Unknown	13 (0.31%)	n/a	n/a	n/a	n/a	36 (0.13%)
Race						
White	1,809 (43.40%)	1,557 (43.66%)	3,283 (45.93%)	3,930 (44.64%)	2,038 (44.68%)	12,617 (44.67%)
Black or African American	643 (15.43%)	687 (19.27%)	1,101 (15.40%)	1,306 (14.83%)	696 (15.26%)	4,433 (15.69%)
Asian	267 (6.41%)	176 (4.94%)	487 (6.81%)	725 (8.23%)	314 (6.88%)	1,969 (6.97%)
Native Hawaiian or Other Pacific Islander	92 (2.21%)	63 (1.77%)	162 (2.27%)	197 (2.24%)	138 (3.03%)	652 (2.31%)
American Indian or Alaska Native	29 (0.70%)	21 (0.59%)	76 (1.06%)	106 (1.20%)	42 (0.92%)	274 (0.97%)
Other Race	1,048 (25.14%)	886 (24.85%)	1,508 (21.10%)	1,750 (19.88%)	860 (18.86%)	6,052 (21.43%)
Declined to answer	15 (0.36%)	20 (0.56%)	38 (0.53%)	68 (0.77%)	61 (1.34%)	202 (0.72%)
Unknown	265 (6.36%)	148 (4.15%)	493 (6.90%)	722 (8.20%)	412 (9.03%)	2,048 (7.25%)
Ethnicity	'	'				
Hispanic or Latino	1,202 (28.84%)	930 (26.08%)	1,788 (25.01%)	2,401 (27.27%)	1,239 (27.17%)	7,560 (26.76%)
Not Hispanic or Latino	2,552 (61.23%)	2,375 (66.60%)	4,828 (67.54%)	5,697 (64.71%)	2,954 (64.77%)	18,406 (65.16%)
Declined to answer	20 (0.48%)	20 (0.56%)	30 (0.42%)	55 (0.62%)	42 (0.92%)	167 (0.59%)
Unknown	394 (9.45%)	241 (6.76%)	502 (7.02%)	651 (7.39%)	326 (7.15%)	2,114 (7.48%)
Virus						
COVID	163 (3.91%)	1,040 (29.16%)	2,071 (28.97%)	943 (10.71%)	421 (9.23%)	4,638 (16.42%)
HMPV	268 (6.43%)	58 (1.63%)	466 (6.52%)	702 (7.97%)	219 (4.80%)	1,713 (6.06%)
RSV	1,663 (39.90%)	845 (23.70%)	1,617 (22.62%)	2,862 (32.51%)	1,945 (42.64%)	8,932 (31.62%)
influenza	597 (14.32%)	n/a	109 (1.52%)	489 (5.55%)	357 (7.83%)	1,556 (5.51%)
parainfluenza virus	186 (4.46%)	252 (7.07%)	421 (5.89%)	675 (7.67%)	227 (4.98%)	1,761 (6.23%)
rhinovirus	1,291 (30.97%)	1,367 (38.33%)	2,464 (34.47%)	3,133 (35.59%)	1,392 (30.52%)	9,647 (34.15%)
Comorbidity						
Asthma	232 (5.57%)	190 (5.33%)	373 (5.22%)	513 (5.83%)	302 (6.62%)	1,610 (5.70%)
Chronic Lung Disease	29 (0.70%)	11 (0.31%)	25 (0.35%)	45 (0.51%)	20 (0.44%)	130 (0.46%)
Chronic Obstructive Pulmonary Disease	n/a	n/a	n/a	11 (0.12%)	n/a	21 (0.07%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 15. Figure 16 shows the same data stacked to represent the combined impact of the viruses.

Figure 15: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five





Figure 16: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



Older adults (age 65 and over)

Our older adults study population consists of 245,573 hospitalizations of 228,742 unique patients (Table 9).

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
Ν	29,190 (100.00%)	59,920 (100.00%)	62,237 (100.00%)	49,362 (100.00%)	28,033 (100.00%)	228,742 (100.00%)
Age Group						
65 - 74 years	12,325 (42.22%)	26,135 (43.62%)	24,030 (38.61%)	16,637 (33.70%)	9,368 (33.42%)	88,495 (38.69%)
75 - 84 years	10,642 (36.46%)	21,877 (36.51%)	23,612 (37.94%)	19,325 (39.15%)	11,009 (39.27%)	86,465 (37.80%)
85+ years	6,223 (21.32%)	11,908 (19.87%)	14,595 (23.45%)	13,400 (27.15%)	7,656 (27.31%)	53,782 (23.51%)
Sex						
Female	14,959 (51.25%)	29,978 (50.03%)	31,856 (51.18%)	26,208 (53.09%)	15,073 (53.77%)	118,074 (51.62%)
Male	14,161 (48.51%)	29,764 (49.67%)	30,183 (48.50%)	23,065 (46.73%)	12,928 (46.12%)	110,101 (48.13%)
Unknown	70 (0.24%)	177 (0.30%)	196 (0.31%)	89 (0.18%)	32 (0.11%)	564 (0.25%)

Tahle 9. Alder	adulta	nationt	characteristics	huspason
TUDIC J. OTUCI	uuuuus	patient	churacteristics	Dy SCUSULI.

Race						
White	18,823 (64.48%)	44,868 (74.88%)	48,214 (77.47%)	37,166 (75.29%)	21,010 (74.95%)	170,081 (74.35%)
Black or African American	3,719 (12.74%)	5,036 (8.40%)	5,171 (8.31%)	4,091 (8.29%)	2,319 (8.27%)	20,336 (8.89%)
Asian	1,229 (4.21%)	1,614 (2.69%)	1,808 (2.91%)	1,912 (3.87%)	969 (3.46%)	7,532 (3.29%)
Native Hawaiian or Other Pacific Islander	42 (0.14%)	83 (0.14%)	120 (0.19%)	77 (0.16%)	40 (0.14%)	362 (0.16%)
American Indian or Alaska Native	67 (0.23%)	136 (0.23%)	179 (0.29%)	220 (0.45%)	90 (0.32%)	692 (0.30%)
Other Race	3,532 (12.10%)	5,472 (9.13%)	4,286 (6.89%)	3,508 (7.11%)	2,004 (7.15%)	18,802 (8.22%)
Declined to answer	90 (0.31%)	161 (0.27%)	197 (0.32%)	225 (0.46%)	151 (0.54%)	824 (0.36%)
Unknown	1,688 (5.78%)	2,550 (4.26%)	2,262 (3.63%)	2,163 (4.38%)	1,450 (5.17%)	10,113 (4.42%)
Ethnicity						
Hispanic or Latino	3,126 (10.71%)	5,558 (9.28%)	4,839 (7.78%)	4,000 (8.10%)	2,413 (8.61%)	19,936 (8.72%)
Not Hispanic or Latino	22,406 (76.76%)	48,413 (80.80%)	52,823 (84.87%)	42,073 (85.23%)	23,919 (85.32%)	189,634 (82.90%)
Declined to answer	114 (0.39%)	240 (0.40%)	267 (0.43%)	278 (0.56%)	166 (0.59%)	1,065 (0.47%)
Unknown	3,544 (12.14%)	5,709 (9.53%)	4,308 (6.92%)	3,011 (6.10%)	1,535 (5.48%)	18,107 (7.92%)
Virus						
COVID	19,057 (65.29%)	58,073 (96.92%)	57,160 (91.84%)	35,203 (71.32%)	16,600 (59.22%)	186,093 (81.35%)
HMPV	1,066 (3.65%)	35 (0.06%)	645 (1.04%)	1,688 (3.42%)	541 (1.93%)	3,975 (1.74%)
RSV	1,551 (5.31%)	319 (0.53%)	952 (1.53%)	1,924 (3.90%)	2,875 (10.26%)	7,621 (3.33%)
influenza	4,798 (16.44%)	67 (0.11%)	1,361 (2.19%)	5,436 (11.01%)	5,595 (19.96%)	17,257 (7.54%)
parainfluenza virus	467 (1.60%)	299 (0.50%)	614 (0.99%)	1,410 (2.86%)	455 (1.62%)	3,245 (1.42%)
rhinovirus	2,251 (7.71%)	1,127 (1.88%)	1,505 (2.42%)	3,701 (7.50%)	1,967 (7.02%)	10,551 (4.61%)
Comorbidity						
Asthma	2,338 (8.01%)	3,665 (6.12%)	4,799 (7.71%)	4,777 (9.68%)	3,137 (11.19%)	18,716 (8.18%)
Chronic Lung Disease	1,855 (6.35%)	3,146 (5.25%)	3,808 (6.12%)	3,756 (7.61%)	2,440 (8.70%)	15,005 (6.56%)
Chronic Obstructive Pulmonary Disease	4,917 (16.84%)	8,848 (14.77%)	11,361 (18.25%)	10,139 (20.54%)	6,331 (22.58%)	41,596 (18.18%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in `Figure 17. Figure 18 shows the same data stacked to represent the combined impact of the viruses.

Figure 17: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older





Figure 18: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Discussion and Conclusion

Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout March 2024 (32.4% decrease since end of February 2024). This is due to the decrease in COVID- (-56.7%), influenza- (-28.4%), and RSV-associated hospitalizations (-57.6%). Hospitalizations for all other monitored respiratory viruses increased. In the last week of March 2024, respiratory virus-associated hospitalizations accounted for 2.6% of all hospitalizations.

For the population between 0-4 years old, respiratory virus-associated hospitalizations slightly increased throughout March (+4.1%). RSV-associated hospitalizations decreased (-37.8%) while other respiratory viruses increased when counts were above reporting thresholds. In the last week of March, 3.2% of all hospitalizations in this age group were associated with a respiratory virus, and rhinovirus-associated hospitalizations were the largest individual contributor (1.7%).

In the population over 65 years of age, there was a 37% decrease in hospitalizations associated with respiratory viruses. COVID-, influenza-, and RSV-associated hospitalizations all continued to decrease throughout the month, while HPMV-, parainfluenza-, and rhinovirus-associated hospitalizations each increased. In the last week of March, 3.1% of all hospitalizations in this age group were associated with a respiratory virus.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed April 15, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., ... Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., ... Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy